All results

1 results for randomized double blind vehicle controlled multicenter phase iii study evaluate

• ALXN2050-NEPH-201

  This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy…

  Ages

  18 Years - 75 Years

  Sexes

  All